[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342753-105":59,"doc-detail-342753-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancing-anticancer-activity-of-macrophages-through-rational-drug-combinations","Enhancing anticancer activity of macrophages through rational drug combinations","","Targeting tumor-associated macrophages (TAMs) is an emerging strategy tested across clinical trials because TAMs can switch between pro- and antitumorigenic states depending on differentiation. In this issue of the JCI, Vaccaro and colleagues use an innovative drug screening approach showing that simultaneous blockade of driver oncogenic signaling pathways and anti-CD47 sensitizes tumor cells to macrophage-induced phagocytosis. The combination changes tumor surface molecules that restrict phagocytosis and reprograms macrophages toward an M1-like antitumor state, with broader applicability across oncogenic pathways and implications for precision oncology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-anticancer-activity-of-macrophages-through-rational-drug-combinations/342753/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-anticancer-activity-of-macrophages-through-rational-drug-combinations/342753.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are tumor-associated macrophages considered a promising target in cancer therapy?","Question",{"text":112,"@type":113},"TAMs can exhibit pro- or antitumorigenic functions depending on their differentiation state. They also contribute to tumor initiation, progression, and therapeutic resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did Vaccaro and colleagues demonstrate in their drug combination approach?",{"text":117,"@type":113},"They used a drug screen to show that targeting driver oncogenic signaling pathways together with anti-CD47 sensitizes tumor cells to macrophage-induced phagocytosis. The combination alters tumor molecules that limit phagocytosis and reprograms macrophages toward an M1-like antitumor state.",{"name":119,"@type":110,"acceptedAnswer":120},"How do “don’t-eat-me” checkpoint proteins affect macrophage phagocytosis and therapy?",{"text":121,"@type":113},"Cancer cells can inhibit macrophage phagocytic activity through checkpoint proteins such as CD47 and CD24. Blocking CD47 interactions (e.g., with anti-CD47 antibodies) can trigger cancer cell phagocytosis and enhance adaptive antitumor immunity in preclinical models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342753,1790978284,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":81,"preview_urls":144},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Clinical Investigation COMMENTARY  \nEnhancing anticancer activity of macrophages through rational drug combinations  \nGordon B. Mills1 and Marilyne Labrie2,3,4  \n1Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. 2Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 3Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke (CRCHUS), Sherbrooke, Quebec, Canada. 4Institut de Recherche sur le Cancer de l’Université de Sherbrooke (IRCUS), Sherbrooke, Quebec, Canada.  \nTargeting tumor-associated macrophages (TAMs) is an emerging approach being tested in multiple clinical trials. TAMs, depending on their differentiation state, can exhibit pro-or antitumorigenic functions. For example, the M2-like phenotype represents a protumoral state that can stimulate tumor growth, angiogenesis, metastasis, therapy resistance, and immune evasion by expressing immune checkpoint proteins. In this issue of the JCI, Vaccaro and colleagues utilized an innovative drug screen approach to demonstrate that targeting driver oncogenic signaling pathways concurrently with anti-CD47 sensitizes tumor cells, causing them to undergo macrophage-induced phagocytosis. The combination treatment altered expression of molecules on the tumor cells that typically limit phagocytosis. It also reprogrammed macrophages to an M1-like antitumor state. Moreover, the approach was generalizable to tumor cells with different oncogenic pathways, opening the door to precision oncology–based rationale combination therapies that have the potential to improve outcomes for patients with oncogene-driven lung cancers and likely other cancer types.  \nMacrophage checkpoint inhibitors expand the immunotherapy arsenal  \nT cell checkpoint inhibitors (ICIs) have transformed the therapy landscape for a number of diseases; however, only a fraction of patients with cancer receive substantial benefit from ICIs. While effective biomarkers for ICI activity remain elusive, their activity hinges on several factors, including the tumor mutation burden and the expression of tumor neoantigens, the  \nexpression of immune checkpoint proteins, intratumoral heterogeneity, and the overall immune landscape (1, 2). Regrettably, these factors limit the activity of current ICIs targeting T cell function in many cancers. For example, a subset of patients with non–small cell lung cancer (NSCLC) who have oncogenic mutations in genes, such as EGFR, ALK, or KRAS, typically respond poorly to ICIs (3) .  \nTumor-associated macrophages (TAMs) have emerged as critical mediators of  \nRelated Article: [https://doi.org/10.1172/JCI169315](https://doi.org/10.1172/JCI169315)  \nConflict of interest: GBM is on the scientific advisory board and/or a consultant for Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, GSK, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, and Zentalis Pharmaceuticals. GMB has stock or receives income from BlueDot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, and Turbine. GBM has licensed technology related a method to identify homologous recombination deficiency with Myriad Genetics and a patent with Nanostring (patent 10,501,777,“Simultaneous quantification of a plurality of proteins in a user defined region or a cross-sectioned tissue”) . GBM also receives income for sponsored research from AstraZeneca.  \nCopyright: © 2024, Mills et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nReference information: J Clin Invest. 2024;134(9):e180512 . [https://doi.org/10.1172/JCI180512](https://doi.org/10.1172/JCI180512) .  \ntumor initiation, progression, and therapeutic resistance (1, 4). Macrophages exhibit remarkable phenotypi","cbCairRsTDj27R8C","https://ap.wps.com/l/cbCairRsTDj27R8C","pdf",1218994,"English","# Enhancing anticancer activity of macrophages through rational drug combinations\n## TAM targeting as an emerging clinical approach\n## M2-like versus M1-like macrophage states and functional plasticity\n# Macrophage checkpoint inhibitors expand the immunotherapy arsenal\n## Limits of T cell checkpoint inhibitors in cancer subsets\n## TAMs, neoantigen presentation, and “don’t-eat-me” signals\n## Anti-CD47 and therapeutic rationale","[{\"question\":\"Why are tumor-associated macrophages considered a promising target in cancer therapy?\",\"answer\":\"TAMs can exhibit pro- or antitumorigenic functions depending on their differentiation state. They also contribute to tumor initiation, progression, and therapeutic resistance.\"},{\"question\":\"What did Vaccaro and colleagues demonstrate in their drug combination approach?\",\"answer\":\"They used a drug screen to show that targeting driver oncogenic signaling pathways together with anti-CD47 sensitizes tumor cells to macrophage-induced phagocytosis. The combination alters tumor molecules that limit phagocytosis and reprograms macrophages toward an M1-like antitumor state.\"},{\"question\":\"How do “don’t-eat-me” checkpoint proteins affect macrophage phagocytosis and therapy?\",\"answer\":\"Cancer cells can inhibit macrophage phagocytic activity through checkpoint proteins such as CD47 and CD24. Blocking CD47 interactions (e.g., with anti-CD47 antibodies) can trigger cancer cell phagocytosis and enhance adaptive antitumor immunity in preclinical models.\"}]","Enhancing anticancer activity of macrophages through rational drug combinations | PDF",1790048022,[145,149,153],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d5fa5b35c760a812372e726d15eded5.webp",983,1315,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/102fb8168ddc3841d3de807b80c8d04e.webp",982,1314,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd0a914eb43e3cadeea4dc4f0b45904a.webp",981,1312]